You’ve always seen it in the movies, a pill that can cure a disease that is usually non-curable with pills, or maybe it’s even a disease that can rarely be combated. This is just fiction, there’s nothing real about those products or those story lines, but there actually is some sort of “miracle pill” on the market. Sovaldi is a brand new hepatitis C drug that is being manufactured by Gilead Sciences, people are just now asking the pharmaceutical giant to tell us why these pills are $1,000 a pop.
The price tag for a three-month cycle of this medicine is definitely for those who would deem themselves “wealthy”, as it comes in at a staggering $84,000; which respectively has health insurance companies and statewide Medicaid programs sweating bullets.
“It makes an easy target, certainly for politicians or for folks, but I think the more important constituency here are our payers,” stated Christopher Raymond, whom is a R.W. Baird biotech analyst. Raymond continued on to say that most biotech companies don’t have to deal with these kinds of problems in other places on our planet, simply because they have a different health care system in place. For example, Europe makes great use of the single-payer systems (which allows for the government to take care of any health-care related costs).
“Alexion (which is another pharmaceutical company), which has their own high-price drug, are in the midst of a new product cycle in Europe where they are winning the battle every day,” he stated. It seems as if this company just wants a “fair play” rule put into place. Raymond continued on saying until the United States adopts a medical care system like this the interactions regarding this matter are going to stay as headlines.
Source:
0 comments:
Post a Comment